11:01 am Immunomedics announces that 5 patients reported a partial response as their best response in the Company’s ongoing Phase I/II clinical trial of IMMU-132 in patients with solid cancers
View todays social media effects on IMMU
View the latest stocks trending across Twitter. Click to view dashboard
See who Immunomedics is hiring next, click here to view
